ITCI250117P60000
- 0.35
- 0.000.00%
Intra-Cellular Therapies Newsroom
Intra-Cellular Therapies Analyst Ratings
A Quick Look at Today's Ratings for Intra-Cellular Therapies(ITCI.US), With a Forecast Between $118 to $140
Baird Downgrades Intra-Cellular Therapies to Neutral From Outperform, $132 Price Target
Intra-Cellular Therapies Price Target Maintained With a $100.00/Share by Needham
Intra-Cellular Therapies Analyst Ratings
Morgan Stanley Downgrades Intra-Cellular Therapies to Equalweight From Overweight, $132 Price Target
Hold Rating on JNJ Amid Uncertainty Over Intra-Cellular Therapies Acquisition Impact
BofA Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $118
Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $140
Mizuho Securities Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)
J.P. Morgan Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating
BofA Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $118
J.P. Morgan Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating
RBC Capital Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Cuts Target Price to $108
RBC Trims Price Target on Intra-Cellular Therapies to $108 From $112, Keeps Outperform Rating
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100
RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)
UBS Maintains Intra-Cellular Therapies(ITCI.US) With Hold Rating, Raises Target Price to $87
Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan